Finance

Lists
Why is PHAT down १०.५६%?
Dive Deeper
PHAT:NASDAQ
Phathom Pharmaceuticals Inc
US$ ५.०८
-१०.५६%
(-०.६०) 1D
US$ ५.०१
-१.४६% (-०.०७४)
After hours
Closed: नोभेम्बर ५, १६:००:०१ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PHAT...
Open
US$ ५.७०
High
US$ ५.७०
Low
US$ ५.०४
Mkt. cap
४१.३० करोड
Avg. vol.
१६.४९ लाख
Volume
१५.५२ लाख
52-wk high
US$ १८.३१
52-wk low
US$ ५.०२
EPS
-US$ १.०३
Beta
०.६९
Shares outstanding
८.१३ करोड
No. of employees
३७१
Open
US$ ५.७०
High
US$ ५.७०
Low
US$ ५.०४
Mkt. cap
४१.३० करोड
Avg. vol.
१६.४९ लाख
Volume
१५.५२ लाख
52-wk high
US$ १८.३१
52-wk low
US$ ५.०२
EPS
-US$ १.०३
Beta
०.६९
Shares outstanding
८.१३ करोड
No. of employees
३७१
News stories
From web sources and news partners
About Phathom Pharmaceuticals Inc
CEO-
Employees३७१
Founded२०१८
HeadquartersFlorham Park, न्यु जर्सी, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Websitephathompharma.com
Analyst ratings
Based on 6 analysts giving stock ratings to PHAT in the past 3 months
Strong buy
Buy
5
Hold
1
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for PHAT in the last 3 months.
Highest
Current US$ ५.०८
US$ २६.०० (+४११.८१%)
Average
US$ १६.९० (+२३२.६८%)
Lowest
US$ ७.५० (+४७.६४%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daniel Clark
Leerink Partners
Hold
Maintained
US$ ७.५०
+४७.६%
11/02/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
US$ २२.००
+३३३.१%
10/29/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
US$ २६.००
+४११.८%
10/30/2026
Jenna Davidner
Barclays
Buy
Maintained
US$ १४.००
+१७५.६%
10/30/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
-
-
10/23/2026
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
US$ १५.००
+१९५.३%
10/21/2026
Martin Auster
Raymond James
Buy
Maintained
US$ २१.००
+३१३.४%
07/31/2026
Joseph Stringer
Needham
Buy
Maintained
US$ २२.००
+३३३.१%
07/30/2026
Paul Choi
Goldman Sachs
Hold
Maintained
-
-
04/30/2026
Last report
२०२६ अक्टोबर २९
Fiscal period
Q3 2026
US$ ०.०४ / US$ ०.०३
+३९.८६%beat
Revenue / Est. (USD)
८.४७ करोड / ८.४८ करोड
-०.१२%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
५.७६ करोड
५.८३ करोड
७.४३ करोड
८.४७ करोड
Cost of goods sold
७६.४८ लाख
१.२० करोड
१.५१ करोड
१.८४ करोड
Cost of revenue
७६.४८ लाख
१.२० करोड
१.५१ करोड
१.८४ करोड
Research and development expenses
७४.९३ लाख
७७.७१ लाख
७८.१३ लाख
८७.४५ लाख
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
४.८४ करोड
५.४० करोड
५.५३ करोड
५.७७ करोड
Operating expense
५.५९ करोड
६.१८ करोड
६.३१ करोड
६.६४ करोड
Total operating expenses
६.३५ करोड
७.३८ करोड
७.८२ करोड
८.४८ करोड
Operating income
-५९.२८ लाख
-१.५५ करोड
-३९.६५ लाख
-८५.०० हजार
Other non operating income
-५.०० हजार
-८.३१ लाख
-२४.०० हजार
-२५.०० हजार
EBT including unusual items
-२.११ करोड
-३.०४ करोड
-१.७६ करोड
-१.३९ करोड
EBT excluding unusual items
-२.११ करोड
-३.०४ करोड
-१.७६ करोड
-१.३९ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-२.११ करोड
-३.०४ करोड
-१.७६ करोड
-१.३९ करोड
Net profit margin
-३६.७३%
-५२.०९%
-२३.६७%
-१६.४०%
Earnings per share
-०.०८
-०.१८
-
०.०४
Interest and investment income
१२.०४ लाख
१७.३६ लाख
१५.१० लाख
१६.०० लाख
Interest expense
-१.६४ करोड
-१.५८ करोड
-१.५१ करोड
-१.५४ करोड
Net interest expenses
-१.५२ करोड
-१.४१ करोड
-१.३६ करोड
-१.३८ करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
-५८.०० लाख
-१.५४ करोड
-३८.५१ लाख
३५.०० हजार
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू